Acute Promyelocytic Leukemia with Hyperleukocytosis: Improving Outcomes with Current Therapy

Sanz MA, Lo Coco F, Martín G et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 96(4):1247–1253

Lo-Coco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 11(369):111–21

Daver N, Kantarjian H, Marcucci G et al (2015) Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 168(5):646–653

Kapoor J, Mirgh SP, Agrawal N et al (2021) High risk acute promyelocytic leukemia—an enigma for hematologists: optimizing treatment with APML-4 protocol. Indian J Hematol Blood Transfus. https://doi.org/10.1007/s12288-021-01478-x

Iland HJ, Bradstock K et al (2012) All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 120(8):1570–1580